CSET's Steph Batalis and Vikram Venkatram shared their expert analysis in an op-ed published by The Bulletin of the Atomic Scientists. The article explores discusses the complexities and challenges of screening DNA synthesis orders to prevent misuse of potentially dangerous genetic sequences.

In response to the Office of Science and Technology Policy's request for input on an AI Action Plan, CSET provides key recommendations for advancing AI research, ensuring U.S. competitiveness, and maximizing benefits while mitigating risks. Our response highlights policies to strengthen the AI workforce, secure technology from illicit transfers, and foster an open and competitive AI ecosystem.

Dr. Steph Batalis and Vikram Venkatram offered the following comment in response to the National Institute of Standards and Technology's request for information on safety considerations for chemical and biological AI models.

Artificial intelligence (AI) tools pose exciting possibilities to advance scientific, biomedical, and public health research. At the same time, these tools have raised concerns about their potential to contribute to biological threats, like those from pathogens and toxins. This report describes pathways that result in biological harm, with or without AI, and a range of governance tools and mitigation measures to address them.

Artificial intelligence is becoming more integrated into the sciences. One of the scientific fields experiencing this is computational biology, which uses computer modeling to understand biological mechanisms and systems. This blog post provides an understanding of important research trends in these subject areas, and how advancements in AI can improve the speed and efficiency of computational biology to improve human health and well-being.

Now that the first set of milestones has passed for the Biden administration’s October 2023 executive order on artificial intelligence, where do things stand for biotech? This blog post gives an overview of the most recent action items, with a recap of expert commentary from CSET’s June 2024 Webinar on the AIxBio Policy Landscape.

On June 6, CSET hosted experts to discuss where AIxBio policymakers go next after the 180-day mark following the Biden AI Executive Order.

Medical artificial intelligence, which depends on large repositories of biological data, can improve public health and contribute to the growing global bioeconomy. Countries that strategically prioritize medical AI could benefit from a competitive advantage and set global norms. This report examines China’s stated goals for medical AI, finding that the country’s strategy for biodata collection and medical AI development positions it to be an economic and technological leader in this sector.

In an article published by Axios that discusses how AI-driven "biosurveillance" could be instrumental in detecting future pandemics or biological attacks, CSET's Steph Batalis provided her expert insights.

As the U.S. government considers banning genomics companies from China, it opens a broader question about how the United States and other market economies should deal with China’s “national champions.” This paper provides an overview of one such company—BGI—and how China’s industrial policy impacts technology development in China and around the world.